# Study Evaluating the Safety and Efficacy of AR-15512

> **NCT05285644** · PHASE3 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 465 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** 0.003% AR-15512 ophthalmic solution
- **DRUG:** AR-15512 vehicle ophthalmic solution

## Key facts

- **NCT ID:** NCT05285644
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-07-24
- **Final completion:** 2023-07-24
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05285644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05285644, "Study Evaluating the Safety and Efficacy of AR-15512". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05285644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*